Abstract
Hepatitis C is the leading cause of chronic hepatitis, cirrhosis, liver cancer and liver transplantation. In 70% to 80% of the people infected, the virus creates a chronic carrier state and the patient will be clinically asymptomatic or have mild symptoms. Two new direct-acting antiviral agents, boceprevir and telaprivir, both protease inhibitors, have been approved by the FDA for treatment of Hepatitis C genotype 1. The current hepatitis C post-exposure protocol is that no immediate post-exposure therapy is advised, but the dental healthcare worker should be tested periodically and offered antiviral therapy if a chronic carrier state exists.
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Carrier State
-
Dental Care for Chronically Ill*
-
Hepatitis C Antibodies / blood
-
Hepatitis C, Chronic / diagnosis
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / epidemiology
-
Humans
-
Infection Control, Dental / methods
-
Oligopeptides / therapeutic use
-
Prevalence
-
Proline / analogs & derivatives
-
Proline / therapeutic use
-
Protease Inhibitors / therapeutic use
Substances
-
Antiviral Agents
-
Hepatitis C Antibodies
-
Oligopeptides
-
Protease Inhibitors
-
telaprevir
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline